Spring Bank Announces Presentation of Promising Results from Study Highlighting Immune-Activation with Inarigivir 400mg
June 06, 2019 08:00 ET
|
Spring Bank Pharmaceuticals, Inc.
HOPKINTON, Mass., June 06, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
Spring Bank Pharmaceuticals to Present at Jefferies 2019 Global Healthcare Conference
May 28, 2019 08:00 ET
|
Spring Bank Pharmaceuticals, Inc.
HOPKINTON, Mass., May 28, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
Spring Bank Pharmaceuticals Reports First Quarter 2019 Financial and Operational Results and Provides Corporate Update
April 29, 2019 07:00 ET
|
Spring Bank Pharmaceuticals, Inc.
ACHIEVE trial completed – inarigivir HBsAg reduction comparable to interferon but with significantly better tolerability profilePhase 2 co-administration study of inarigivir + nucleotide analogue...
Spring Bank Announces Positive Results from the Recently Completed Phase 2 Chronic Hepatitis B ACHIEVE Trial and Additional Inarigivir Studies
April 12, 2019 06:00 ET
|
Spring Bank Pharmaceuticals, Inc.
Consistent reduction in HBV DNA demonstrated with higher inarigivir doses including in high viral burden HBeAg-positive patients 26% HBsAg responder population for all inarigivir doses showed mean...
Spring Bank to Host a Conference Call to Discuss Inarigivir Data Presented at the International Liver Congress™ (EASL 2019)
April 10, 2019 16:01 ET
|
Spring Bank Pharmaceuticals, Inc.
HOPKINTON, Mass., April 10, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
Spring Bank Announces Inarigivir Abstracts Accepted for Oral and Poster Presentations at The International Liver Congress™ (EASL 2019)
March 28, 2019 08:00 ET
|
Spring Bank Pharmaceuticals, Inc.
Full inarigivir (IRIG) 200mg cohort results to be presented as a late breaker oral presentation at General Session II and Award Ceremony I Poster presentation to describe the antiviral activity...
Spring Bank Pharmaceuticals to Participate in Jefferies 2019 HBV Summit
March 14, 2019 08:00 ET
|
Spring Bank Pharmaceuticals, Inc.
HOPKINTON, Mass., March 14, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
Spring Bank Pharmaceuticals Reports 2018 Fourth Quarter and Full-Year Financial Results and Corporate Highlights
March 11, 2019 06:30 ET
|
Spring Bank Pharmaceuticals, Inc.
Conference Call to be Held at 8:00 am Eastern TimeInarigivir Late-Breaker Abstract Accepted for Oral Presentation at EASL The International Liver Congress 2019 HOPKINTON, Mass., March 11, 2019 ...
Spring Bank to Host Conference Call to Discuss Fourth Quarter and Fiscal Year 2018 Results on Monday, March 11
March 04, 2019 16:01 ET
|
Spring Bank Pharmaceuticals, Inc.
HOPKINTON, Mass., March 04, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
Spring Bank Pharmaceuticals Appoints Atif Abbas, M.D., as Vice President, Head of Oncology & Immunology Clinical Development
February 19, 2019 16:38 ET
|
Spring Bank Pharmaceuticals, Inc.
HOPKINTON, Mass., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...